An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
Tumors
DRUG: BIBF 1120
Maximum Tolerated Dose (MTD) of BIBF 1120, Up to 7 months|Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120, Up to 7 months
Transfer constant (Ktrans), Screening, day 2, 28 and 56|Extravascular-extracellular leakage volume (ve), Screening, day 2, 28 and 56|Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd]), Screening, day 2, 28 and 56|Relative blood volume (rBV), Screening, day 2, 28 and 56|Mean transit time (MTT), Screening, day 2, 28 and 56|Relative blood flow (rBF), Screening, day 2, 28 and 56|Volume of tumour showing contrast uptake, Screening, day 2, 28 and 56|Volume of tumour showing no contrast uptake, Screening, day 2, 28 and 56|Restricted diffusion, Screening, day 2, 28 and 56|Vessel size index, Screening, day 2, 28 and 56|Change in Eastern Cooperative Oncology Group (ECOG) performance score, Baseline, up to 7 months|Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST), Baseline, up to 7 months|Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1), up to 24 hours after the first dose on day 1|Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz), up to 24 hours after the first dose on day 1|Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞), up to 24 hours after the first dose on day 1|Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1), up to 24 hours after the first dose on day 1|Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1), up to 24 hours after the first dose on day 1|Terminal half-life (t1/2), up to 24 hours after the first dose on day 1|Mean residence time (MRTpo), up to 24 hours after the first dose on day 1|Apparent clearance (CL/F), up to 24 hours after the first dose on day 1|Apparent volume of distribution during the terminal phase (Vz/F), up to 24 hours after the first dose on day 1|Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss), up to 24 hours after drug administration on day 27|Predose plasma concentration at steady state immediately before dosing (Cpre,ss), up to 24 hours after drug administration on day 27|Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss), up to 24 hours after drug administration on day 27|Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss), up to 24 hours after drug administration on day 27|Terminal half-life at steady state (t1/2,ss), up to 24 hours after drug administration on day 27|Apparent clearance at steady state (CL/F,ss), up to 24 hours after drug administration on day 27|Mean residence time at steady state (MRTpo,ss),, up to 24 hours after drug administration on day 27|Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss), up to 24 hours after drug administration on day 27|Accumulation ratio (RA), up to 24 hours after drug administration on day 27|Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1), up to 24 hours after the first dose on day 1|Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1), up to 24 hours after the first dose on day 1|Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss), up to 24 hours after drug administration on day 27|Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss), up to 24 hours after drug administration on day 27|Predose concentration of the 15th dose over the dosing interval τ (Cpre,15), pre-dose on day 15
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))